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Introduction
Autophagy is an evolutionally conserved and a self-destructive process, which is induced by various stimuli, including nutrient depletion and genotoxic stress (1) . Autophagy functions as the elimination of intracellular parasites, harmful aggregated proteins and excess or damaged organelles within characteristic vacuoles known as the autophagosome, which is fused with lysosome to become the autolysosome.
Autophagy is essential for a long-term survival mechanism when cells suffer nutrient starvation. Inhibition of autophagy results in rapid cell death under conditions of starvation or withdrawal of growth factors (2) . In some cancer cells, autophagy is induced by chemotherapy or radiotherapy and may protect cells undergoing apoptosis (programmed type-I cell death), resulting in unfavorable conditions after anticancer therapy (2) . In contrast, several studies have reported that autophagy triggers apoptosis-independent cell death in response to various anticancer agents, including sodium trioxide, tamoxifen, temozolomide, nelfinavir (3) and plumbagin (4) . Thus, autophagy is also implicated in promoting cellular suicide (programmed type-II cell death), presumably due to irreversible massive self-destruction of cellular contents or activation of death signal pathways (5) . In human glioma cells, autophagy provides a protective mechanism of cancer cells against radiotherapy and chemotherapy (6-9); in contrast, some anticancer agents, including minocycline, oncolytic adenovirus, α-mangostin and curcumin, have been reported to induce autophagic cell death (10) (11) (12) (13) . Whether autophagy provides survival or induction of cell death in glioma cells remains controversial.
Phosphatidylinositol 3-kinase (PI3K) is an enzyme that is activated by diverse signaling agents, including platelet-derived growth factor, epidermal growth factor and insulin-like growth factor-1. It phosphorylates PI(4,5)P 2 to generate PI(3,4,5)P 3 , resulting in the functional activation of Akt (protein kinase B). Activated Akt phosphorylates a series of protein substrates that function as a regulator of cell proliferation, growth and cell survival. PI3K/Akt signaling is commonly hyperactivated in various cancer types and often confers a poor prognosis (14, 15) . PTEN (phosphatase and tensin homolog deleted on chromosome 10), also known as MMAC1 (mutated in multiple advanced cancer) or TEP1 (TGFβ-regulated and epithelial cell-enriched phosphatase), is a lipid phosphatase that removes the 3′-phosphate group from PI(3,4,5)P 3 and converts it to PI(4,5)P 2 , thereby negatively regulating the PI3K/Akt signal pathway. Loss of PTEN activity is known to be caused by chromosomal gene mutation, epigenetic silencing due to DNA methylation in the promoter region of the gene or aberrant proteolytic events, which is responsible for the deregulated activation of PI3K/Akt signaling (16) . Accumulating evidence has suggested that the PI3K/Akt pathway plays an important role in the regulation of autophagy (17, 18) . Indeed, the PI3K inhibitor LY294002 and Akt inhibitor 7-hydroxystaurosporine synergistically augment rapamycininduced autophagy (19) and inhibition of the PI3K/Akt pathway by curcumin exposure induces non-apoptotic autophagic cell death in PTEN-null U-87MG malignant glioma cells (13) .
2-Chloro-10-[3(-dimethylamino) propyl] phenothiazine monohydrochloride (chlorpromazine; CPZ) is a phenothiazine derivative belonging to the first generation of a typical antipsychotic agent. In addition to dopamine receptor antagonistic activity (20) , CPZ may bind to several proteins, including calmodulin (CaM), several channel proteins, DNA topoisomerase, oncogenic K-Ras and other membrane proteins (21, 22) . CPZ shows beneficial effects on the antiproliferation of various tumor cells (23, 24) , probably through inhibition of the mitotic kinesin KSP/Eg5 that results in mitotic arrest (25) , upregulation of p21
Waf1/Cip1 expression via activation of tumor-suppressor Egr-1 or through inhibition of the 3-phosphoinosite-dependent protein kinase 1/Akt signaling pathway (26) . However, whether CPZ stimulates autophagy in human glioma cells is still unknown.
The aim of this study was to obtain insight into the action of CPZ in the regulation of autophagy and the functional role of autophagy on tumor cell growth in PTEN-null U-87MG glioma cells. To establish this, we analyzed cell cycle control, long-term clonogenic survival, apoptosis and autophagy following CPZ treatment. We found that CPZ induces apoptosis-independent autophagic cell death and inhibits clonogenicity of U-87MG cells in vitro and xenografted tumor growth Cell viability and cell proliferation assay U-87MG cells (2 × 10 3 cells per sample) seeded into 96 well plates were treated with CPZ at increasing concentrations (0, 10, 20 and 40 μM) for different time periods (0, 24 and 48 h). For cell viability, a Cell Counting Kit-8™ (Dojindo Molecular Technologies) was used, according to the manufacturer's instructions. For cellular proliferation, cells were labeled with bromodeoxyuridine (BrdU) for 2 h, and the incorporation of BrdU was measured using an ELISA Cell Proliferation Assay Kit (Cell Signaling Technology), according to the manufacturer's instructions.
Cell death analysis
At indicated time points, U-87MG cells were trypsinized and washed in phosphate-buffered saline (PBS), and treated with 2.5 μg/ml propidium iodide (PI) for 5 min at room temperature. For quantification of dead cells, PI-stained cells were analyzed using a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). U-87MG cells (5 × 10 3 cells per well) were counted and plated onto 24 well tissue culture plates (BD Falcon TM ; Becton Dickson Immunocytometry System) in DMEM supplemented with 10% fetal bovine serum. After attachment, the cells were treated with CPZ for 7 days. The cells were then fixed with 6% glutaraldehyde and stained with 0.1% crystal violet, as described previously (27) .
Clonogenic survival assay
Cell cycle analysis U-87MG cells were treated with 20 μM CPZ for 12 and 24 h, fixed in 70% ethanol, washed twice with PBS and stained with 50 μg/ml PI, as described previously (28) . The cellular DNA content was analyzed, and the population in the sub-G 0 /G 1 phase of the cell cycle was measured by flow cytometry in a FACSCalibur.
Western blot analysis
Cells were lysed in a buffer containing 20 mM hydroxyethyl piperazineethanesulfonic acid (pH 7.2), 1% Triton X-100, 10% glycerol, 150 mM NaCl, 10 μg/ ml leupeptin and 1 mM phenylmethylsulfonyl fluoride. Western blotting was performed as described previously (28) . Signals were developed using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Piscataway, NJ). Electron microscopy U-87MG cells either left untreated or treated with CPZ for 24 h were fixed with a solution of 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.4) for 2 h and postfixed with 1% phosphate-buffered osmium tetroxide for 1 h. They were then dehydrated using a graded series of ethanol solutions ranging from 30 to 100%, transferred to propylene oxide and embedded in Epon (Polybed 812; Polysciences, Warrington, PA), as described previously (29) . Ultrathin sections were prepared using an ultramicrotome (Leica Microsystems, Bannockburn, IL) and stained with 2% uranylacetate in 50% methanol and lead citrate. They were finally examined using an H-7650 transmission electron microscope (Hitachi, Tokyo, Japan) at an accelerating voltage of 80 kV. 
Green

Generation of U-87MG variant cells stably expressing Beclin 1 small interfering RNA
U-87MG cells were transduced with MISSION® small hairpin RNA lentiviral particles expressing scrambled small interfering RNA (siRNA) or Beclin 1 siRNA (Sigma-Aldrich, St Louis, MO), according to the manufacturer's instructions. Twenty-four hours postinfection, 2 μg/ml of puromycin was added to select for infected cells. After 2 weeks, silencing of Beclin 1 expression was verified by western blotting.
In vivo tumor xenograft study
Xenograft tumor experiments were performed as described previously (30) . Briefly, for the subcutaneous xenograft tumor model, U-87MG glioma cells (1 × 10 6 cells in 100 μl of serum-free DMEM) were inoculated subcutaneously into the right flank of 5-to 6-week-old athymic nude mice (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea). Tumor growth was measured at intervals of every 2-3 days with calipers. The tumor volume was calculated as (L × W 2 )/2, where L is the length and W is the width in millimeters. When the tumors reached a mean volume of ~100 mm 3 , 100 μl of PBS (control group) or CPZ (20 mg/kg) was injected intraperitoneally daily. Mice were killed by exposure to CO 2 on day 24 to compare the tumor size on cutaneous xenograft tumors.
For the intracranial xenograft tumor model, the mice were anesthetized with zoletil (30 mg/kg; Virbac Laboratories, Carros, France) and xylazine (5 mg/ kg; Bayer Korea, Anseong, Korea). The surgical area over the parieto-occipital bone was applied with disinfectant, and an ~1 cm long sagittal incision was made using a scalpel. A 0.9 mm burr hole was drilled into the skulls at 2.0 mm to the right of the bregma and 1.0 mm anterior to the coronal suture, and U-87MG cells (1 × 10 5 cells in 10 μl of serum-free DMEM) were inoculated using a 10 μl Hamilton syringe, followed by covering the hole in sterile bone wax. After 4 days, PBS (control group) or CPZ (20 mg/kg) was injected intraperitoneally daily for 7 days. All mouse studies were performed at the veterinary facilities of Konkuk University in accordance with the Institutional Animal Care and Use Committee of Konkuk University.
Immunohistochemical analysis
Immunohistochemistry was performed using Vectastain Elite ABC Kits (Vector Laboratories, Burlingame, CA). LC3b monoclonal antibody (1:100; Abcam Corp., Cambridge, UK) was used as the primary antibody. Briefly, paraffin sections were deparaffinized, hydrated and heated in 0.01M sodium citrate for 10 min in a microwave to retrieve antigen. The sections were treated with 3% hydrogen peroxide in methanol and incubated with 5% bovine serum albumin. The brain sections were then incubated with the primary antibody overnight at 4°C. After washing in PBS, the sections were incubated with biotinylated secondary antibodies for 60 min and with avidin-biotin peroxidase complex for 30 min at room temperature. The sections were visualized with peroxidase substrate kits (Vector Laboratories) for immune reactivity, counterstained with hematoxylin and dehydrated in ethanol.
Statistical analysis
Each experiment was repeated at least three times. The data were plotted as the mean ± SD. Two-tailed Student's t-test was used for comparisons, and a value of P < 0.05 was deemed to be statistically significant.
Results
CPZ promotes antitumoral action through induction of cell death
We first assessed the effectiveness of CPZ ( Figure 1A ) as a therapeutic agent in human gliomas. Exponentially growing PTEN-null U-87MG glioma cells were exposed to different concentrations of CPZ, and cellular proliferation was tested based on the incorporation of BrdU during DNA synthesis. A decrease in cellular proliferation was observed in cells treated with CPZ in a dose-and time-dependent manner compared with untreated control cells ( Figure 1B , top graph). Cell viability was determined to examine the cytotoxic effects of CPZ using a Cell Counting Kit-8™. A significant decrease in cell viability was observed in cells treated for 24 h with high concentration of CPZ (≥20 μM) compared with untreated control cells ( Figure 1B , bottom graph), probably due to the promotion of cell death. To address whether CPZ causes cell death, U-87MG cells were treated with CPZ for 24 h and stained with PI, which is an intercalating agent that can be used for identifying dead cells in a population. Flow cytometric analysis showed that CPZ caused cell death in a dose-dependent fashion ( Figure 1C ). The clonogenic (or colony forming) assay is based on the ability of a single cell to grow into a viable colony and is considered to be a reliable test for predicting the effectiveness of cytotoxic agents. To assess the longterm efficacy of CPZ, the clonogenic survival assay was performed. Significant decreases in the number of colonies were observed for U-87MG glioma cells after treatment with CPZ ( Figure 1D ). These results demonstrated that CPZ exhibits antitumor activity through induction of cell death.
CPZ triggers cell cycle arrest at the G 2 /M phase and apoptosisindependent cell death
To determine whether the antitumor activity of CPZ is associated with inhibition of cell cycle progression, the cell cycle distribution profile was analyzed using flow cytometric analysis. Cells in the G 0 /G 1 phase slowly decreased with a concomitant increase in G 2 /M phase cells after treatment with CPZ ( Figure 2A) . Notably, accumulation of sub-G 1 phase cells, a hallmark of apoptosis, was not detected until 24 h after CPZ treatment. We next examined the effects of CPZ on the expression of cell cycle regulatory proteins. Immunoblot analysis showed that after 12 h of CPZ exposure, the levels of cyclin A and cyclin B1 decreased, whereas levels of cyclin D1, proliferating cell nuclear antigen and GAPDH remained unchanged ( Figure 2B ), suggesting that CPZ causes inhibition of cell cycle progression. As a flow cytometric analysis failed to reveal accumulation of cells in the sub-G 0 /G 1 phase following CPZ treatment, we further examined the effect of CPZ on the induction of apoptosis. One of the earliest cellular changes during apoptosis is the translocation of phosphatidylserine (PS), a membrane phospholipid, from the inner to the outer membrane (31) . To determine the appearance of PS at the outer membrane following CPZ treatment, Annexin V staining was performed. Doxorubicin was used as a positive control. We found no sign of PS translocation to the outer membrane in U-87MG cells treated with CPZ compared with that in control cells ( Figure 2C ). The processing of native 113 kDa PARP to its 89-and 24 kDa forms by caspase-3 or -7 can be induced in the early stage of apoptosis. However, treatment with CPZ for 24 h failed to cleave PARP, whereas ultraviolet irradiation or doxorubicin treatment for 24 h, used as positive controls for apoptosis, caused cleavage of PARP ( Figure 2D) . Furthermore, the pan-caspase inhibitor zVAD-fmk had no effect on CPZ-induced cell death ( Figure 2E ). These data suggest that CPZ may trigger cell death through apoptosis-independent mechanism in U-87MG cells.
CPZ induces autophagy
Two forms of programmed cell death exist; type-I (apoptosis) and type-II (autophagic cell death). Because CPZ treatment did not display typical apoptotic features, we next asked whether CPZ induces cell death through autophagy in U-87MG cells. Transmission electron microscopy (EM) revealed that CPZ treatment resulted in the appearance of numerous vacuoles, containing cellular fragments, whereas the nucleus maintained its integrity (Figure 3A) , manifesting the typical feature of autophagy.
During autophagy, the18 kDa LC3-I protein is known to be cleaved to 16 kDa and conjugated to phosphatidylethanolamine (2) to form LC3-II, which is localized on the autophagosome membrane (32, 33) . LC3-I exhibits a diffuse staining pattern within the cytoplasm, whereas LC3-II is visualized in small puncta corresponding to the autophagosome (33) . To verify the formation of the autophagosome by CPZ, we transiently transfected U-87MG cells with the expression plasmid for GFP-LC3. GFP-LC3-transfected cells showed a diffuse distribution of green fluorescence in the absence of CPZ ( Figure 3B ). In contrast, CPZ triggered the formation of punctated structures of GFP-LC3. We next determined the localization of endogenous LC3 using immunofluorescence staining. Similar to exogenous GFP-LC3, endogenous LC3 displayed the formation of a punctated fluorescent pattern in response to CPZ treatment ( Figure 3C ), representing an association of LC3-II with the autophagosome. , and wholecell lysates were then subjected to western blotting using antibody against LC3b. GAPDH antibody was used as an internal control to show equal protein loading. (F) U-87MG cells were treated with 10 nM bafilomycin A1 (BafA1) for 30 min, followed by 20 μM CPZ for 24 h. Western blotting was performed as in (E). (G) U-87MG cells were treated with 10 nM BafA1 and 20 μM CPZ for 24 h as in (F) and then stained with 2.5 μg/ml PI for 5 min. PI-positive (dead) cells were assessed by flow cytometry.
As the amount of LC3-II is correlated with the extent of autophagic vesicle formation, conversion of LC3-I to LC3-II serves as a hallmark for accumulation of the autophagosome and autophagic activity (33) . To determine whether CPZ increases LC3-II formation in U-87MG cells, western blot analysis was performed using an antibody against LC3. CPZ treatment resulted in an increase in the amount of LC3-II in a time-and dose-dependent manner ( Figure 3D and E). LC3-II accumulation can result from either the enhancement or inhibition of ongoing autophagic flux. To discriminate between these possibilities, bafilomycin A1, a vacuolar H + -ATPase inhibitor, was used to prevent autophagosome-lysosome fusion. Treatment with bafilomycin A1 alone led to an increase in the amount of LC3-II, and the addition of CPZ to cells pretreated with bafilomycin A1 further increased the LC3-II level ( Figure 3F ), suggesting that CPZ enhances autophagic flux. As bafilomycin A1 alone triggered cell death ( Figure 3G ), we suggest that the prolonged inhibition of ongoing autophagic flux may promote cell death in U-87MG cells. Collectively, our results suggest that CPZ induces autophagy, probably by promoting autophagic vesicle formation, in U-87MG glioma cells.
Beclin 1 is required for CPZ-induced autophagy
Autophagy is controlled by a series of autophagy-related genes (ATGs). We examined whether CPZ alters the expression of ATG proteins. Western blot analysis showed that the protein levels of ATGs, except for LC3-II, did not change in response to CPZ treatment (Supplementary Figure 1 , available at Carcinogenesis Online). Beclin 1, a mammalian ortholog of yeast Atg6/Vps30, is part of the class III PI3K multiprotein complex that participates in autophagosome nucleation (18, (34) (35) (36) . To investigate whether Beclin 1 is required for CPZ-induced autophagy in U-87MG cells, we established stable cell lines expressing Beclin 1 siRNA (U-87/siBECN1) and negative control siRNA (U-87/siCT). Knockdown of Beclin 1 expression was evaluated by western blotting. We found that CPZ-induced LC3-II accumulation was markedly reduced in U-87/siBECN1 cells compared with U-87/siCT cells ( Figure 4A ), suggesting that CPZ-induced autophagy requires Beclin 1-mediated pathway.
To advance our understanding of the role of CPZ induction of autophagy, we evaluated the consequence of disrupting autophagy in CPZ-induced antitumor activity. Knockdown of Beclin 1 had no effect on CPZ-induced G 2 /M cell cycle arrest ( Figure 4B) , suggesting that the induction of autophagy and cell cycle arrest in response to CPZ might be controlled by distinct mechanisms. In contrast, lack of Beclin 1 expression led to an abrogation of CPZ-induced cell death ( Figure 4C ). To further address the role of autophagy, we knocked down another autophagy-related protein, ATG5. ATG5 is involved in LC3-II conjugation to phosphatidylethanolamine, which is necessary for the elongation of autophagic vesicles. We found that CPZ-induced LC3-II accumulation and cell death were attenuated by the knock down of ATG5 (Supplementary Figure 2 , available at Carcinogenesis Online). These results underscore the impact of autophagy on CPZ-induced cell death. Collectively, our studies suggest that induction of autophagy by CPZ may function to contribute to CPZ-triggered cell death in U-87MG glioma cells. Furthermore, CPZ had no effect on the cleavage of PARP, but it induced LC3-II formation (Supplementary Figure 3A , available at Carcinogenesis Online) and reduced cell viability (Supplementary 
CPZ inhibits mTOR by inhibiting Akt
The Akt/mTOR signaling pathway negatively regulates the induction of autophagy and is constitutively activated due to mutation of PTEN in U-87MG glioma cells. To clarify the signaling pathways responsible for CPZ-induced autophagy in U-87MG cells, we examined the effect of CPZ on the phosphorylated status of Akt and mTOR by western blot analysis. The levels of phosphorylated Akt (Ser473) and its downstream effectors GSK3β (Ser9) and mTOR (Thr2481) notably decreased in a time-dependent manner following CPZ treatment ( Figure 5A ). The phosphorylation of p70S6K (Thr389), a downstream effector of mTOR, also decreased. These data suggest that CPZ inhibits mTOR through the inhibition of AKT.
To investigate whether inhibition of the Akt/mTOR pathway is involved in CPZ-induced autophagy, U-87MG cells were treated with the PI3K inhibitor LY294002, and accumulation of LC3-II was measured by western blotting. Treatment with LY294002 alone resulted in the promotion of LC3-I conversion to LC3-II and further enhanced CPZ-induced accumulation of LC3-II ( Figure 5B ). On the contrary, exogenous expression of AKT inhibited CPZ-induced LC3-II formation ( Figure 5C ) and prevented CPZ-induced inhibition of cell proliferation ( Figure 5D ). These results suggest that inhibition of the AKT/ mTOR pathway may participate to CPZ induction of autophagy in U-87MG glioma cells. . Whole-cell lysates were prepared and subjected to western blotting using antibodies against the indicated proteins. GAPDH antibody was used as an internal control to show equal protein loading. (B) U-87MG cells were treated with 20 μM CPZ, 25 μM LY294002 (LY) or CPZ plus LY for 0.5 or 24 h, as indicated. Whole-cell lysates were prepared and subjected to western blotting using an antibody against phosphorylated AKT (Ser473) or LC3b, respectively. Akt or GAPDH antibody was used as an internal control to show equal protein loading. (C) U-87MG cells were transiently transfected with an expression plasmid for AKT (pSG5/AKT) or empty vector. After 48 h, cells were collected and subjected to western blotting using antibodies against AKT and LC3b. Anti-GAPDH antibodies were used as an internal control to show equal protein loading. The relative band intensity of LC3b-II normalized to GAPDH was determined in three independent experiments by quantitative densitometry (bottom graph). *P < 0.05. (D) U-87MG cells (1 × 10 3 cells per sample) transfected with empty vector (Vec) or an expression plasmid for AKT (pSG5/AKT) were treated without (Cont) or with 20 μM CPZ for 24 or 48 h, and cell viability was measured using a Cell Counting Kit-8. The data represent the means ± SD of two independent experiments performed in triplicate.
CPZ induction of autophagic cell death
CPZ inhibits xenograft tumor growth in nude mouse
To determine whether CPZ inhibits tumor growth in vivo, U-87MG glioma cells were inoculated subcutaneously into the flanks of athymic nude mice. At 12 days postimplantation, tumor-bearing mice were administered CPZ (20 mg/kg) intraperitoneally once a day. CPZ treatment inhibited xenograft tumor growth on day 24 compared with PBS (control) treatment. Inhibition of tumor growth by CPZ began to be observed after day 17; on day 24, the tumor size of the CPZ-treated group significantly decreased from 690 ± 112 mm 3 in the control group to 390 ± 81 mm 3 in the CPZ-treated group, accounting for a 43.5% inhibition in tumor growth ( Figure 6A) .
To further evaluate the therapeutic effect of CPZ in the brain, U-87MG cells were implanted into the brain of athymic nude mouse. After 4 days, tumor-bearing mice were administered CPZ intraperitoneally (20 mg/kg/day). CPZ treatment significantly delayed tumor development as revealed by hematoxylin-stained sections ( Figure 6B ). Immunohistochemical staining revealed LC3 puncta in the tumor tissues that received CPZ (Figure 6C ), suggesting the induction of autophagy in xenograft intracranial tumors by CPZ. To further confirm the induction of autophagy in vivo, EM analysis was performed. Tumor regions in mice that received CPZ increased the presence of vacuoles ( Figure 6D ), suggesting that CPZ can achieve effective circulating levels to inhibit tumor growth of brain xenografts through, at least in part, stimulating autophagy in vivo.
Discussion
CPZ was first developed as a neuroleptic agent for the control of psychotic symptoms, such as schizophrenia and bipolar disorder. In addition to antipsychotic actions, CPZ exerts antitumor activity in numerous types of cancer (23, 24) . However, the effect of CPZ on the induction of autophagy has not been studied. In this study, we show that CPZ induces autophagic cell death but not apoptosis through modulation of the Akt/mTOR signaling pathway as well as through inhibition of cell cycle progression in PTEN-null U-87MG glioma cells.
CPZ inhibited tumor cell growth, as revealed by deregulation of cell cycle progression, induction of cell death, inhibition of long-term clonogenic survival and inhibition of xenograft intracranial tumor growth in vivo. The fluorescence-activated cell sorting analysis of our study showed that CPZ caused a decrease in the population of the G 0 / G 1 phase with a concomitant increase in G 2 /M phase cells. This result is consistent with a previous report showing that the antiproliferative effects of CPZ is linked to mitotic arrest through inhibition of the motor activity of the mitotic kinesin KSP/Eg5 in HCT116 and A549 cells (25) . We also previously reported that CPZ induces cell cycle arrest through induction of p21/Waf1/Cip1 in rat C6 glioma cells (28) . Thus, CPZ has the ability to reduce the proliferation of U-87MG cells, presumably by inhibiting cell cycle progression.
Programmed cell death is processed morphologically and is defined as two types; apoptosis (type-I) and autophagic cell death (type-II). Apoptosis is mediated by a cascade of a caspase family activation and leads to cellular shrinkage with chromatin condensation and nuclear fragmentation. Autophagy is mediated by activation of a series of ATG proteins and is characterized by accumulation of acidic vesicular organelles engulfing bulk cytoplasmic organelles such as mitochondria, the Golgi apparatus, polyribosomes and the endoplasmic reticulum. Our results clearly indicate that CPZ triggered cell death in U-87MG glioma cells but had no effect on the occurrence of a sub-G 0 /G 1 population of the cell cycle, the presence of PS on the outer cell membranes and the expression of PARP cleavage. Additionally, inhibition of caspases by pan-caspase inhibitor zVAD-fmk treatment did not alter CPZ-induced cell death, suggesting that apoptosis is not involved in CPZ-induced cell death of U-87MG glioma cells. We further examined whether autophagy is involved in CPZ-induced cell death in U-87MG cells. Our data demonstrated that CPZ significantly increased the vacuoles in the cytoplasm as revealed by EM analysis. We also found the presence of the punctated form of LC3 in CPZ-treated U-87MG cells. Time course experiments revealed detectable increases in the levels of LC3-II within 6 h of CPZ exposure. Knockdown of Beclin 1 by siRNA in U-87MG cells prevented CPZ-induced LC3-II accumulation. Thus, CPZ induces autophagy through Beclin 1-dependent pathway. Furthermore, knockdown of Beclin 1 resulted in blockade of CPZ-induced cell death. Numerous reports have demonstrated that autophagy can be induced in cancer cells that are resistant to radiotherapy and chemotherapy. Thus, although accurate molecular hallmarks and methods for measuring autophagic cell death specifically have not been established until now, we conclude that autophagy contributes to CPZ-induced cell death in U-87MG glioma cells.
PTEN is a tumor suppressor that modulates cell growth and survival by inhibiting the PI3K/Akt pathway. It also plays a role in enhancing autophagy. In fact, overexpression of PTEN prevents interleukin 13-induced suppression of autophagy in colon cancer cells (17) . In U-87MG glioma cells, PTEN is not functional due to a frameshift mutation (16, 37) , resulting in the constitutive activation of the PI3K signaling pathway. mTOR is a member of the PI3K-related kinase family, which is involved in growth regulation, proliferation and cell metabolism (38) . mTOR is a downstream effector of the PI3K/Akt signaling pathway. PTEN enhances autophagy (17) , whereas Akt/ mTOR inhibits autophagy through phosphorylation of Atg13, a component of the autophagy-initiating kinase Atg1 complex, which is involved in the activation of Vps34, a class III PI3K (18) . This study demonstrated that CPZ inhibited mTOR by inhibiting Akt in U-87MG glioma cells. Indeed, inhibition of PI3K by LY294002 treatment alone induced accumulation of LC3-II, and combined treatment with CPZ and LY294002 more potently enhanced LC3-II formation, whereas exogenous expression of AKT partially prevented CPZ-induced autophagy and cell death. However, the mechanism by which CPZ modulates AKT remains unknown.
Phenothiazines, such as CPZ, are strong CaM antagonist (39) . CaM is a ubiquitous intracellular Ca 2+ receptor (40) , and Ca 2+ -bound CaM (Ca 2+ /CaM) targets many proteins that are involved in Ca 2+ -mediated regulation of gene expression and regulation of cellular proliferation processes, including cell cycle progression (41, 42) . Ca 2+ /CaM is also directly bound to the p110γ subunit of PI3K and plays a critical role in the activation of Akt and cell proliferation in diverse cell types (43, 44) . Furthermore, Ca 2+ /CaM is associated with neurotrophin-induced activation of Akt, whereas abolition of intracellular Ca 2+ or CaM inhibits Akt activation (44) (45) (46) . Akt is also phosphorylated and activated by Ca 2+ /CaM-dependent protein kinase kinase through a PI3K-independent pathway, which in turn phosphorylates Bcl-2 antagonist of cell death (BAD) and protects NG108 cells from serum withdrawal-induced apoptosis (47) , implicating the role of Ca 2+ / CaM in activation of Akt via PI3K-dependent and PI3K-independent pathways. Furthermore, inhibition of CaM-dependent protein kinase kinase or CaM-dependent protein kinase reduced starvation-induced autophagy (48) . These results raise the possibility that CPZ could inhibit Akt phosphorylation through the inhibition of Ca 2+ /CaM signaling to release mTOR inhibition of autophagy. Indeed, we also found that other structurally unrelated CaM antagonists, such as W-7 and W-13, could induce LC3-II formation in U-87MG cells (Supplementary Figure 4 , available at Carcinogenesis Online).
Beclin 1 has been found to be a Bcl-2-interacting protein that contains a Bcl-2-homology-3 (BH3) domain. Beclin 1 also interacts with the class III PI3K family and plays a central role in regulating autophagy (34, 36) . The human Beclin 1 gene is localized to chromosome 17q21, a tumor-susceptibility locus that is deleted in up to 75% of ovarian cancers (49), 50% of breast cancers (50) and 40% of prostate cancers (51) . Allelic deletion of the Beclin 1 gene was found in 41% of tested breast cancer cell lines (52) . In normal breast epithelial cells, Beclin 1 is ubiquitously expressed but is frequently low or undetectable in malignant breast epithelial cells, suggesting that decreased expression of Beclin 1 may be important in breast cancer development (34) . In glioblastoma cells, Beclin 1 protein levels are often reduced during gliomagenesis (53) and high levels of Beclin 1 expression are positively correlated with high prognosis (54) . Our study clearly showed that silencing of Beclin 1 by siRNA blocked CPZ-induced cell death, which provided further evidence to support the role of Beclin 1 in antitumor activity in PTEN-deleted human malignant glioma.
In conclusion, this study demonstrated that the antipsychotic agent CPZ triggers apoptosis-independent autophagic cell death in PTEN-null U-87MG glioma cells. Given that CPZ is widely available and can readily cross the blood-brain barrier and accumulate in the brain, the results of our study may help to promote the potential use of the CPZ as a therapeutic supplement for PTEN-mutated human gliomas.
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